Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures : A Danish Nationwide Study. / Loft, Nikolai; Egeberg, Alexander; Isufi, Daniel; Rasmussen, Mads K.; Bryld, Lars E.; Dam, Tomas N.; Ajgeiy, Kawa K.; Bertelsen, Trine; Skov, Lone.
In: Acta Dermato-Venereologica, Vol. 103, adv12616, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures
T2 - A Danish Nationwide Study
AU - Loft, Nikolai
AU - Egeberg, Alexander
AU - Isufi, Daniel
AU - Rasmussen, Mads K.
AU - Bryld, Lars E.
AU - Dam, Tomas N.
AU - Ajgeiy, Kawa K.
AU - Bertelsen, Trine
AU - Skov, Lone
N1 - Publisher Copyright: © 2023, Medical Journals/Acta D-V. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Whether response to an interleukin (IL-17) inhibitor is different in patients with previous exposure to an IL-17 inhibitor compared with patients with exposure to biologics with other cytokine targets remains to be elucidated. Therefore, the aim of this study was to assess whether previous exposure to an IL-17A inhibitor was associated with worse response than exposure to (an)other biologic(s). All patients in the DERMBIO register treated with an IL-17A inhibitor (secukinumab or ixekizumab) were included. With an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 as response, the proportion of responders treated with IL-17A inhibitors was assessed in patients previously treated with another IL-17A inhibitor and compared with patients with previous exposure to (an)other biologic(s), using a χ2 test. In total, 100, 93 and 83 patients with previous exposure to an IL-17A inhibitor and 414, 372 and 314 patients with previous exposure to (an) other biologic(s) were assessed after 3, 6 and 12 months, respectively. No differences in the proportion of patients achieving PASI ≤ 2 were observed between the 2 groups after 3 months (54% vs 57%, p = 0.59), 6 months (70% vs 66%, p = 0.42) and 12 months (69% vs 60%, p = 0.14). In conclusion, when treating patients with IL-17A inhibitors the cytokine target of the previous biologic does not appear to affect the response.
AB - Whether response to an interleukin (IL-17) inhibitor is different in patients with previous exposure to an IL-17 inhibitor compared with patients with exposure to biologics with other cytokine targets remains to be elucidated. Therefore, the aim of this study was to assess whether previous exposure to an IL-17A inhibitor was associated with worse response than exposure to (an)other biologic(s). All patients in the DERMBIO register treated with an IL-17A inhibitor (secukinumab or ixekizumab) were included. With an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 as response, the proportion of responders treated with IL-17A inhibitors was assessed in patients previously treated with another IL-17A inhibitor and compared with patients with previous exposure to (an)other biologic(s), using a χ2 test. In total, 100, 93 and 83 patients with previous exposure to an IL-17A inhibitor and 414, 372 and 314 patients with previous exposure to (an) other biologic(s) were assessed after 3, 6 and 12 months, respectively. No differences in the proportion of patients achieving PASI ≤ 2 were observed between the 2 groups after 3 months (54% vs 57%, p = 0.59), 6 months (70% vs 66%, p = 0.42) and 12 months (69% vs 60%, p = 0.14). In conclusion, when treating patients with IL-17A inhibitors the cytokine target of the previous biologic does not appear to affect the response.
KW - biologics
KW - IL-17
KW - ixekizumab
KW - psoriasis
KW - secukinumab
KW - switch
U2 - 10.2340/actadv.v103.12616
DO - 10.2340/actadv.v103.12616
M3 - Journal article
C2 - 37987625
AN - SCOPUS:85177700201
VL - 103
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
M1 - adv12616
ER -
ID: 387825253